Ailin Closes a Financing Round of 1.5 Million Euros

The biotech startup Ailin has closed its first official round of financing, reaching a figure of 1.5 million euros. “This round has been possible thanks to the support of private investors and the public support of the [Center for Technological Development and Innovation] Cdti through the Neotec program,” the company explains in a statement.

Ailin, in the beginning, raised funds from FFF to start her path . Now, despite the challenging market circumstances, the start-up “exceeds its initial fundraising expectations.”

The round has been subscribed by a family office with ties to the health sector, positioning themselves as strategic investors . Business Angels with experience in private equity , consulting and serial entrepreneurs have also participated , along with two funds also related to the healthcare field, including Decelera Ventures.

If you want to read more about Ailin and find the latest business news of the day, download for free our companion app Born2Invest. Don’t waste your time scrolling the internet, let our team of seasoned writers do that for you, so you can stay on top of the market.

Ailin plans to multiply the growth in billing by ten and reach more than 10,000 patients in 2024

The investment “will boost Ailin’s technological development, incorporating Artificial Intelligence algorithms to provide more accurate health diagnoses.” In addition, a significant part of the funds will go towards hiring professionals to strengthen the team.

“This round of investment will allow us to advance in the development of a new market category that brings diagnostic tests closer to the home and seeks to promote a health model more focused on prevention ,” says the founder and CEO of Ailin, Isabel Caruana.

Ailin is a diagnostic support solutions platform that offers people the possibility of knowing and monitoring their health status from their homes , anytime they want.

The start-up claims to have “multiplied by seven” its growth in 2023, with an “average monthly increase of 60% in the last quarter.” In that sense, by 2024 it hopes to “multiply the growth in billing by ten and reach more than 10,000 patients.”

__

(Featured image by Mathieu Stern via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us